We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+50.74%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$318M
Cap. Flow
+$94.6M
Cap. Flow %
8.53%
Top 10 Hldgs %
61.72%
Holding
56
New
18
Increased
10
Reduced
10
Closed
12
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
1 year
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$46.5M
2
ARVN icon
Arvinas
ARVN
+$39.2M
3
ASMB icon
Assembly Biosciences
ASMB
+$35.2M
4
IPHA icon
Innate Pharma
IPHA
+$27.9M
5
MRUS icon
Merus
MRUS
+$25M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$69.3M
2
ARGX icon
argenx
ARGX
+$44.5M
3
SLDB icon
Solid Biosciences
SLDB
+$34.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$8.42M

Sector Composition

Rank Sector Weight
1 Healthcare 95%
2 Miscellaneous 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PVLA icon
26
Palvella Therapeutics
PVLA
$1.78B
$9.18M 0.83%
+31,690
New +$8.79M
2019 Q4
0 quarters
FATE icon
27
Fate Therapeutics
FATE
$228M
$8.83M 0.8%
+451,354
New +$7.17M
2019 Q4
0 quarters
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.38M 0.76%
65,000
+20,779
+47% +$2M
2018 Q4
4 quarters
RCUS icon
29
Arcus Biosciences
RCUS
$2.82B
$7.37M 0.66%
729,905
-24,600
-3% -$207K
2018 Q1
7 quarters
EOLS icon
30
Evolus
EOLS
$493M
$7.3M 0.66%
+600,000
New +$8.46M
2019 Q4
0 quarters
EIGR
31
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.7M 0.6%
14,978
-20,357
-58% -$7.22M
2018 Q2
6 quarters
SVRA icon
32
Savara
SVRA
$935M
$6.42M 0.58%
+1,432,664
New +$1.72M
2019 Q4
0 quarters
IOVA icon
33
Iovance Biotherapeutics
IOVA
$6.31B
$5.91M 0.53%
+213,647
New +$4.86M
2019 Q4
0 quarters
RUBY
34
DELISTED
Rubius Therapeutics, Inc
RUBY
$5M 0.45%
525,877
+265,725
+102% +$2.57M
2018 Q3
5 quarters
KRSA
35
Korsana Biosciences, Inc. Common Stock
KRSA
$1.53B
$4.93M 0.44%
12,936
+7,392
+133% +$4.83M
2019 Q2
2 quarters
XFOR icon
36
X4 Pharmaceuticals
XFOR
$252M
$4.45M 0.4%
+13,847
New +$4.97M
2019 Q4
0 quarters
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$797M
$4.01M 0.36%
+737,612
New +$2.58M
2019 Q4
0 quarters
ACRS icon
38
Aclaris Therapeutics
ACRS
$492M
$3.94M 0.36%
+2,087,312
New +$3.46M
2019 Q4
0 quarters
IGMS icon
39
DELISTED
IGM Biosciences
IGMS
$3.82M 0.34%
100,000
– –
2019 Q3
1 quarter
TCRR
40
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.42M 0.31%
+239,500
New +$3.7M
2019 Q4
0 quarters
CTMX icon
41
CytomX Therapeutics
CTMX
$516M
$3.41M 0.31%
+410,000
New +$2.77M
2019 Q4
0 quarters
SURF
42
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.45M 0.22%
1,301,713
-247,175
-16% -$412K
2018 Q2
6 quarters
VCEL icon
43
Vericel Corp
VCEL
$2.11B
$2.28M 0.21%
131,001
– –
2019 Q1
3 quarters
UROV
44
DELISTED
Urovant Sciences Ltd.
UROV
$411K 0.04%
+26,468
New +$287K
2019 Q4
0 quarters
ASMB icon
45
CALL
Assembly Biosciences
ASMB
$411M
– –
-41,525
Closed -$4.9M –
AUTL icon
46
Autolus Therapeutics
AUTL
$447M
– –
-69,155
Closed -$859K –
CRIS icon
47
Curis
CRIS
$946K
– –
-7,456
Closed -$6.68M –
GOSS icon
48
CALL
Gossamer Bio
GOSS
$54.1M
– –
-10,000
Closed -$13.4M –
LRMR icon
49
Larimar Therapeutics
LRMR
$202M
– –
-162,042
Closed -$1.44M –
NXTC icon
50
NextCure
NXTC
$27.8M
– –
-20,875
Closed -$7.73M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2019 Portfolio in Review

As of Q4 2019, EcoR1 Capital held 56 positions worth $1.11B, up 40% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

EcoR1 Capital deployed $94.6M of net new capital in Q4 2019, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was AnaptysBio: 1,966,100 shares worth $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $44.5M trimmed.

  • EcoR1 Capital's largest Q4 2019 buy was AnaptysBio: 1,966,100 shares worth $31.9M.
  • EcoR1 Capital added most to Assembly Biosciences in Q4 2019, an estimated $35.2M increase.
  • EcoR1 Capital's biggest Q4 2019 reduction was argenx, cutting an estimated $44.5M.
  • EcoR1 Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $69.3M.
  • EcoR1 Capital's ten largest holdings make up 62% of its $1.11B portfolio in Q4 2019.
  • EcoR1 Capital opened 18 new positions and closed 12 in Q4 2019.
  • EcoR1 Capital's portfolio value rose 40% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.